Floatz logo

Irinotecan

Hepatosplenic T-cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Hepatosplenic T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
City of Hope Medical Center
Phase 4BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
cc-5013
University of Nebraska
Phase 2BB
DEXAMETHASONE
University of Nebraska
Phase 2BB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →